Biomarker Discovery and Validation Laboratory, LifeGene-Biomarks, Toa Baja, Puerto Rico.
Internal Medicine Department, San Juan Bautista School of Medicine, Caguas, Puerto Rico.
Immun Inflamm Dis. 2024 Jun;12(6):e1285. doi: 10.1002/iid3.1285.
As the SARS-CoV-2 virus spread throughout the world, millions of positive cases of COVID-19 were registered and, even though there are millions of people already vaccinated against SARS-CoV-2, a large part of the global population remains vulnerable to contracting the virus. Massive nasopharyngeal sample collection in Puerto Rico at the beginning of the pandemic was limited by the scarcity of trained personnel and testing sites. To increase SARS-CoV-2 molecular testing availability, we evaluated the diagnostic accuracy of self-collected nasal, saliva, and urine samples using the TaqPath reverse transcription polymerase chain reaction (RT-PCR) COVID-19 kit to detect SARS-CoV-2. We also created a colorimetric loop-mediated isothermal amplification (LAMP) laboratory developed test (LDT) to detect SARS-CoV-2, as another strategy to increase the availability of molecular testing in community-based laboratories. Automated RNA extraction was performed in the KingFisher Flex instrument, followed by PCR quantification of SARS-CoV-2 on the 7500 Fast Dx RT-PCR using the TaqPath RT-PCR COVID-19 molecular test. Data was interpreted by the COVID-19 Interpretive Software from Applied Biosystems and statistically analyzed with Cohen's kappa coefficient (k). Cohen's kappa coefficient (k) for paired nasal and saliva samples showed moderate agreement (0.52). Saliva samples exhibited a higher viral load. We also observed 90% concordance between LifeGene-Biomarks' SARS-CoV-2 Rapid Colorimetric LAMP LDT and the TaqPath RT-PCR COVID-19 test. Our results suggest that self-collected saliva is superior to nasal and urine samples for COVID-19 testing. The results also suggest that the colorimetric LAMP LDT is a rapid alternative to RT-PCR tests for the detection of SARS-CoV-2. This test can be easily implemented in clinics, hospitals, the workplace, and at home; optimizing the surveillance and collection process, which helps mitigate global public health and socioeconomic upheaval caused by airborne pandemics.
随着 SARS-CoV-2 病毒在全球范围内传播,数以百万计的 COVID-19 阳性病例被登记,尽管已经有数百万人接种了 SARS-CoV-2 疫苗,但很大一部分全球人口仍然容易感染该病毒。在大流行初期,波多黎各的大规模鼻咽样本采集受到训练有素的人员和检测地点稀缺的限制。为了增加 SARS-CoV-2 分子检测的可用性,我们使用 TaqPath 逆转录聚合酶链反应 (RT-PCR) COVID-19 试剂盒评估了自我采集的鼻、唾液和尿液样本对 SARS-CoV-2 的诊断准确性。我们还创建了一种比色环介导的等温扩增 (LAMP) 实验室开发的测试 (LDT),以检测 SARS-CoV-2,作为增加社区实验室分子检测可用性的另一种策略。在 KingFisher Flex 仪器中进行自动 RNA 提取,然后在 7500 Fast Dx RT-PCR 上使用 TaqPath RT-PCR COVID-19 分子测试对 SARS-CoV-2 进行 PCR 定量。数据由 Applied Biosystems 的 COVID-19 解释软件进行解释,并使用 Cohen's kappa 系数 (k) 进行统计学分析。配对的鼻和唾液样本的 Cohen's kappa 系数 (k) 显示出中度一致性 (0.52)。唾液样本显示出更高的病毒载量。我们还观察到 LifeGene-Biomarks 的 SARS-CoV-2 快速比色 LAMP LDT 与 TaqPath RT-PCR COVID-19 测试之间的 90%一致性。我们的结果表明,自我采集的唾液样本比鼻和尿液样本更适合 COVID-19 检测。结果还表明,比色 LAMP LDT 是 RT-PCR 检测 SARS-CoV-2 的快速替代方法。该测试可以在诊所、医院、工作场所和家庭中轻松实施;优化监测和收集过程,有助于减轻由空气传播的大流行对全球公共卫生和社会经济的影响。